Retatrutide Explained: The Triple Receptor Agonist Peptide
By Peptura Research Team/10 February 2025/7 min read
The Molecule in Brief
Retatrutide is a synthetic peptide built to act as a triple receptor agonist, hitting three targets in parallel: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Developed by Eli Lilly, it marks a clear step beyond the dual agonists such as Tirzepatide and the single agonists such as Semaglutide that preceded it. That triple reach is exactly why it now sits among the most actively investigated peptides in metabolic science.
How the Three Arms Work Together
The compound signals at three distinct receptor pathways at the same time. GLP-1 receptor activity ties into insulin-secretion modulation and appetite-signalling research. GIPR activity shapes insulin and glucagon secretion in glucose-dependent settings. Glucagon receptor agonism reaches hepatic glucose output and energy-expenditure pathways. Folding all three into one peptide gives researchers an unusually rich tool for studying metabolic regulation, energy homeostasis, and the crosstalk between receptors in laboratory models.
Set Against Semaglutide and Tirzepatide
Semaglutide works through a single GLP-1 receptor. Tirzepatide adds GIP to make a dual agonist. Retatrutide layers glucagon receptor agonism on top of both, and the research to date suggests that third arm drives more pronounced effects on energy-expenditure pathways than either predecessor. Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 reported notable metabolic outcomes, which is much of the reason interest in Retatrutide as a research compound rose so sharply.
Where It Stands Clinically
As of 2024 Retatrutide remains in Phase 3 clinical trials. No regulator, the MHRA and FDA included, has approved it for human use. Any work involving the compound belongs in a controlled laboratory setting, conducted under the appropriate ethical and safety frameworks.
Reconstitution and Handling
Retatrutide ships as a lyophilised powder. Hold it at -20°C until you are ready to work. To reconstitute, inject bacteriostatic water slowly down the inner wall of the vial and swirl gently, never shake. After reconstitution keep the solution at +4°C and use it within four weeks, handling under sterile conditions from start to finish.
Sourcing Research Peptides in the UK
Peptura supplies research-grade Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg as lyophilised powder from GMP-certified manufacturers, each with full batch documentation. Available to buy in the UK with fast Royal Mail tracked delivery. For laboratory and in-vitro research use only. Browse all products.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.